文献速递临床试验与 GCP

肺动脉高压患者运动康复多中心随机对照试验方案更新:SPHERe试验

Protocol update for a multi-centre randomised controlled trial of exercise rehabilitation for people with pulmonary hypertension: the SPHERe trial.
PubMed 文献 · Trials · 2024-07-20

SPHERe试验是一项多中心、实用性随机对照试验,评估监督下运动康复联合心理社会与动机支持相比最佳实践常规照护对肺动脉高压患者的临床与成本效果。首例参与者于2020年1月随机化,因COVID-19疫情于2020年3月停止,干预从中心康复改为远程在线小组课程,并相应微调入选标准。SPHERe是首个评估在线小组康复项目对比常规照护对肺动脉高压患者临床与成本效果的随机对照试验。

要点

  • SPHERe试验评估监督下运动康复联合心理社会与动机支持对比最佳实践常规照护的临床与成本效果。
  • 因COVID-19疫情,干预从中心康复改为远程在线小组课程,入选标准有微调。
  • SPHERe是首个评估在线小组康复项目对比常规照护对肺动脉高压患者效果的随机对照试验。

核心结论

  • 描述了因COVID-19疫情限制而修改的SPHERe试验方案,SPHERe是首个评估在线小组康复项目对比常规照护对肺动脉高压患者临床与成本效果的随机对照试验。

研究设计与样本

  • 多中心、实用性、随机对照试验,评估监督下运动康复联合心理社会与动机支持对比最佳实践常规照护对肺动脉高压患者的临床与成本效果。
  • 首例参与者于2020年1月随机化,试验因COVID-19疫情于2020年3月停止。
  • 试验注册号ISRCTN 10608766,于2019年3月18日前瞻性注册,2023年8月16日更新。

主要发现

  • 因COVID-19疫情对临床易感肺动脉高压人群的限制,试验实施从中心康复项目改为远程在线小组课程。
  • 上述改变导致入选标准有轻微调整。
  • 改变经与利益相关方及肺动脉高压患者协商,并由资助方和独立试验委员会批准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SPHERe (Supervised Pulmonary Hypertension Exercise Rehabilitation) trial is a multi-centre, pragmatic, randomised controlled trial assessing the clinical and cost-effectiveness of supervised exercise rehabilitation with psychosocial and motivational support compared to best-practice usual care for people with pulmonary hypertension (PH). The original protocol was published in BMC Pulmonary Medicine (accessible online). We randomised our first participant in January 2020. In response to the COVID-19 pandemic, the trial was stopped in March 2020. In person delivery of the SPHERe intervention to a vulnerable population was not possible during the COVID-19 pandemic. We describe here how trial procedures and intervention delivery were adapted in response to the COVID-19 pandemic. METHODS: Restrictions imposed by the COVID-19 pandemic on the clinically vulnerable PH population meant that trial delivery was changed from a centre-based rehabilitation programme to remotely delivered group online sessions. This led to minor alterations to the eligibility criteria. These changes followed a consultation process with stakeholders and people with PH and were approved by the funder and independent trial committees. CONCLUSIONS: We describe the modified SPHERe trial protocol in response to restrictions imposed by the COVID-19 pandemic. SPHERe is the first randomised controlled trial to assess the clinical and cost-effectiveness of an online group rehabilitation programme for people with PH compared to usual care. TRIAL REGISTRATION: ISRCTN no. 10608766. Prospectively registered on 18th March 2019, updated 16th August 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ennis S, Bruce J, Sandhu H, et al. Protocol update for a multi-centre randomised controlled trial of exercise rehabilitation for people with pulmonary hypertension: the SPHERe trial. Trials. 2024. PMID: 39033102. doi:10.1186/s13063-024-08341-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。